Radiation exposure and protection advice after [177Lu]Lu-DOTA-TATE therapy in China Authors: Fei Liu, Panli Li, Junyan Xu, Jianping Zhang, Xiaoping Xu, Zhihao Chen, Ying Qiao, Yun Liang, Jie Chen, Shaoli Song Published: 2024 ABSTRACT AbstractBackgroundWe conducted a study on radiation exposure in patients with gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) treated with [177Lu]Lu-DOTA-TATE in China for the first time, aiming to provide guidance and reference for radiation protection in this regard. A total of 30 GEP-NENs patients who received [177Lu]Lu-DOTA-TATE therapy were recruited in the study. We measured the external dose rate (EDR) values of each patient during the injection and 0–6 h post-administration period, as well as the radiation dose (RD) values to healthcare nurses and the surrounding environment. We performed a double exponential curve fitting and estimated the RD to the public from patients discharged at different times after [177Lu]Lu-DOTA-TATE therapy.ResultsAmong the 30 patients, 27 patients completed 4 cycles of [177Lu]Lu-DOTA-TATE treatments, the estimated RD to the public indicated that for adult family members, children above 10 years old, children aged 3–10 and coworkers of the patients, patients could begin daily contact at least 24 h, 48 h, 144 h and 192 h after injection to ensure that the total RD values after four treatments not exceed the limit. During the hospitalization of patients receiving [177Lu]Lu-DOTA-TATE, the cumulative dose received by the administering nurses and to the ward environment were both well below the national RD limits.ConclusionsThis study conducted a fitting analysis of the decay pattern of EDR values in GEP-NENs patients undergoing [177Lu]Lu-DOTA-TATE therapy, in order to establish guidelines for patient discharge timing and provide recommendations for radiation protection for the general public after patient discharge.Trial registration A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs, NCT05459844. https://clinicaltrials.gov/study/NCT05459844?cond=NCT05459844&rank=1. Registered 5 July 2022.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13550-024-01185-4.Keywords: GEP-NENs, [177Lu]Lu-DOTA-TATE, Radiation exposure, Dosimetry, Patient discharge Background Neuroendocrine neoplasms (NENs) are a highly heterogeneous type of neoplasms derived from neuroendocrine cells which can occur in various systems and organs throughout the body. Over the past 30 years, the incidence of NENs has increased nearly sixfold [1, 2]. Among NENs, gastroenteropancreatic NENs (GEP-NENs) are the most common type [3]. In China, the incidence of NENs has reached to 4.1 cases per 100,000 people, unlike Western countries, GEP-NENs are most commonly occurred in pancreas, followed by rectum, stomach, appendix, small intestine, and colon [4]. Approximately 90% of NENs express somatostatin receptors (SSTRs), with SSTR2 being the most commonly expressed subtype among the five SSTRs [5]. Based on the mitotic count and/or the Ki-67 proliferation index, NENs can be classified into three grades: low-grade G1, intermediate-grade G2 and high-grade G3. In China, the majority of GEP-NENs are well-differentiated G1 and G2 tumors [4, 6]. Peptide receptor radionuclide therapy (PRRT) is a targeted new method for treating GEP-NENs by labeling therapeutic radionuclides with peptides that target tumor cells with high expression of specific receptors. The emitted radiation from the radionuclide helps in killing the tumor cells [7, 8]. [177Lu]Lu-DOTA-TATE injection (Lutathera) is a commonly used PRRT method targeting SSTRs for treating GEP-NENs. The results of the NETTER-1 study showed that [177Lu]Lu-DOTA-TATE significantly improved the progression-free survival (PFS) of midgut NENs, with a clear trend towards overall survival (OS) benefit. During a long-term follow-up, the [177Lu]Lu-DOTA-TATE group had a lower rate of grade ≥ 3 treatment-related severe adverse events and exhibited a good safety profile [9, 10]. Several single-center or multi-center series studies confirmed that [177Lu]Lu-DOTA-TATE is a favorable and relatively safe treatment option for well-differentiated G1-G2 GEP-NENs [11–13]. [177Lu]Lu-DOTA-TATE was approved by the European Medicines Agency (EMA) in September 2017 and by the U.S. Food and Drug Administration (FDA) in January 2018 for the treatment of GEP-NENs [9, 13]. In clinical practice, PRRT is a second-line treatment option for high-differentiated GEP-NENs with positive SSTRs expression, and it has received recommendations from the European Association of Nuclear Medicine guidelines, National Comprehensive Cancer Network (NCCN) Neuroendocrine Tumor Guidelines, and Chinese Society of Clinical Oncology (CSCO) Neuroendocrine Tumor Diagnosis and Treatment Guidelines [12, 14]. However, in China, [177Lu]Lu-DOTA-TATE injection has not yet been marketed domestically, thus failing to meet the treatment needs of domestic patients. 177Lu is a relatively popular radiotherapeutic isotope in recent years. Obtained through neutron irradiation inside a nuclear reactor, 177Lu has a longer half-life (T1/2 = 6.65 d) compared to 90Y (T1/2 = 64.20 h), making it convenient for long-distance transport and greatly enhancing its practicality [15]. The low β− particle (0.498 MeV) is the primary mode of therapeutic action for 177Lu, and studies have shown that low-energy β− particles have higher absorption fractions, resulting in greater absorbed doses in tumors. Additionally, 177Lu has a short maximum range in soft tissue with only 2.2 mm, significantly reducing radiation to adjacent normal tissues [16, 17]. Radiation protection is a crucial component of PRRT. Due to the emission of β and γ particles during the decay of 177Lu, there is external exposure to healthcare nurses around the patient during treatment and to the patient’s family members post-treatment. Therefore, [177Lu]Lu-DOTA-TATE therapy must be conducted in hospitals with nuclear medicine facilities by healthcare nurses trained in nuclear medicine safety standards, with patients undergoing a period of isolation post-treatment. However, opinions differ internationally regarding the location for [177Lu]Lu-DOTA-TATE therapy and discharge criteria. In some countries, outpatient administration is chosen, while in others, patients are required to stay in specialized nuclear medicine wards for 24–72 h before discharge [18, 19]. The European Commission Basic Safety Standards Ionising Radiations Regulations 2017 (IRR17) stipulated that the annual effective dose limit for the public should not exceed 1 mSv. To meet this requirement, PRRT patients might need inpatient treatment. Some countries set discharge criteria as having an external dose rate at a distance of 1 m (EDR-1 m) below 40 μSv/h, while others lower the threshold to below 25 μSv/h [19]. Currently in China, various medical institutions have different norms and guidelines for hospitalization and discharge of patients undergoing [177Lu]Lu-DOTA-TATE treatment, and there are no specific radiation protection standards related to [177Lu]Lu-DOTA-TATE. In our study, we conducted a phase III clinical trial of [177Lu]Lu-DOTA-TATE in patients with GEP-NETs who are unresectable or have metastatic, progressive, well-differentiated (G1 and G2) and SSTR-positive. We also conducted the radiation exposure study in GEP-NENs patients treated with [177Lu]Lu-DOTA-TATE for the first time in China, aiming to provide reference for relevant radiation protection measures. Materials and methods Patients The prospective study included 30 patients who received [177Lu]Lu-DOTA-TATE treatment in the Department of Nuclear Medicine at Fudan University Shanghai Cancer Center (FUSCC) from May 2023 to March 2024. The inclusion criteria for patients were: (1) age ≥ 18 years; (2) histologically confirmed unresectable or metastatic, progressive, well-differentiated (G1 and G2), SSTR-positive GEP-NENs; (3) at least one measurable lesion on baseline imaging and all target lesions confirmed as SSTR-positive (lesion uptake greater than normal liver uptake) by 68 Ga-DOTA-TATE positron emission tomography/computed tomography (PET/CT); (4) ECOG performance status of 0 or 1; (5) premenopausal patients willing to use contraception during and after treatment (4 months for males, 7 months for females). Patients with any of the following conditions were excluded from the study: serum creatinine > 1.7 mg/dL, hemoglobin < 80 g/L, white blood cell < 2.0 × 109/L, platelets < 75 × 109/L, serum total bilirubin > 3 times the upper limit of normal (ULN), serum albumin < 30 g/L, alanine aminotransferase (ALT) or glutamic pyruvic transaminase (AST) > 2.5 × ULN, international normalized ratio (INR) > 1.5. This study was approved by the Ethics Committee of FUSCC (Approval No. 2210262-2), and all patients provided informed consent. [177Lu]Lu-DOTA-TATE PRRT protocol The dosage of [177Lu]Lu-DOTA-TATE was 7.4 GBq (200 mCi) ± 10% per cycle, with a total of 4 cycles administered every 8 ± 2 weeks. The interval between two cycles was at least 6 weeks and up to a maximum of 16 weeks. In case of drug-related adverse events during treatment, dosing might be temporarily paused, reduced, or discontinued based on the specific circumstances (Supplemental Table 1). On the day of [177Lu]Lu-DOTA-TATE treatment, patients were admitted to a nuclear medicine ward equipped with specialized radiation protection measures. Patients were first given ondansetron hydrochloride injection to prevent nausea, followed by intravenous infusion of amino acids (arginine hydrochloride and lysine hydrochloride) 30 min after antiemetic administration to reduce radiation damage to the kidneys caused by [177Lu]Lu-DOTA-TATE [20], with the total duration of amino acid administration exceeding 4 h. The injection of [177Lu]Lu-DOTA-TATE was carried out 30 min after the start of amino acid infusion using an automated infusion device with shielding protection, and the administration duration exceeds 30 min [21]. After receiving radiation safety education, each patient was discharged at least 4 h after receiving [177Lu]Lu-DOTA-TATE to protect others from unnecessary radiation exposure. Table 1Basic information of the patients (n = 30)CharacteristicPatients n (%)Average (range)Age (years)53.27 (25–70)Gender Male16 (53.33) Female14 (46.67)Primary lesion Pancreas18 (60.00) Rectum12 (40.00)Adverse reaction Thrombocytopenia (≥ Grade 2)3 (10.00) Neutropenia (≥ Grade 3)2 (6.67)Numbers of treatments 21 (3.33) 32 (6.67) 427 (90.00)Accumulated dose (GBq) 2 cycles15.44 3 cycles22.67 (22.44–22.90) 4 cycles29.89 (26.60–31.32) Basic information of the patients (n = 30) After each administration of [177Lu]Lu-DOTA-TATE at 4, 24, 96 and 144 h, we performed whole-body single photon emission computed tomography (SPECT) imaging and localized tomographic imaging of metastatic lesions. A clinical SPECT/CT scanner (Discovery NM/CT 670, GE, USA) equipped with low energy high resolution (LEHR) collimator and energy window of 113 ± 10% keV was used. The CT parameters were as follows: tube voltage = 120 kV, tube current = 20 mA, slice thickness = 3.75 mm. The ordered subset expectation maximization (OSEM) algorithm was applied for reconstruction. And for corrections, resolution recovery, scatter and attenuation corrections were used. Measurement method of EDR Following the initiation of [177Lu]Lu-DOTA-TATE infusion, a portable x/γ radiation dose (RD) detector (SG-16A) (Jiufu Technology Co., Ltd, China) was used to measure the EDR on the patient’s chest every 5 min until the completion of [177Lu]Lu-DOTA-TATE infusion. After the completion of [177Lu]Lu-DOTA-TATE infusion, at immediate post-infusion, 0.5, 1, 1.5, 2, 3 and 4 h, and/or pre-discharge time points, patients were instructed to measure the EDR-1 m value from the front surface of each patient’s body and at a height of 1.5 m above the floor, with each patient measurement exceeding 4 h. The EDR-1 m value measurement was performed using the TOFTEK TERM-35 environmental radiation monitor (Tongtou Optoelectronic Technology Co., Ltd, China). EDR decay curve fitting method The decay law of EDR over time in vitro was analyzed using MATLAB_R2018.a software (MathWorks Inc., USA), the EDR values measured at 1–5 h, which were relatively stable and have high discriminative power, were fitted using a double exponential parameter model. The mean EDR values of all populations undergoing [177Lu]Lu-DOTA-TATE therapy and different treatment frequencies were also fitted. By fitting a double exponential function model to the data and obtaining the corresponding equation, we calculated the effective half-life of [177Lu]Lu-DOTA-TATE. The quality of the model fit was evaluated using the R2 and root mean square error (RMSE) values, where a higher R2 value and lower RMSE value indicated a better fit of the double exponential curve model, aligning more closely with dosimetry and pharmacokinetic studies. Estimation radiation dose of direct family members To estimate the RD received by the public or family members, the Mountford method was employed [22], assuming exposure patterns to estimate the RD for the public. We assume the contact distance for direct family members and co-workers with the patient after administration is 1.0 m, with contact times of 6 h per 24 h and 8 h per 24 h, respectively. Based on the calculation method for public RD outlined by National Council on Radiation Protection and Measurements (NCRP) Report No. 155 [23], and considering different occupancy factors for various human activities, the formula for calculating the public RD for the [177Lu]Lu-DOTA-TATE patients under different activity patterns from the time post-administration to infinite time of exposure is as follows: Here, the expression ∑i=12FiTeieln2tTei represents the exponential function modeling the metabolism of [177Lu]Lu-DOTA-TATE in the human body using a compartmental model. Fi denotes the relative distribution fractions of [177Lu]Lu-DOTA-TATE in each compartment, Tei represents the effective half-life of [177Lu]Lu-DOTA-TATE (h), DR(rj) and OF(rj) refer to the dose rate and occupancy factor at a distance of rj, and t signifies the time of intravenous administration of [177Lu]Lu-DOTA-TATE (h). According to the Chinese Requirements for Radiological Protection in Nuclear Medicine GBZ 120–2020, the RD limits for patients receiving radionuclide therapy are typically set at 1 mSv/year for general public, and for direct family members, the RD limits are set at 1 mSv/year for children aged 3–10, 3 mSv/year for children older than 10, and 5 mSv/year for adult family members. We calculated the recommended social contact times for different populations using the formula. Radiation dose measurement to staff During the patient’s hospitalization, a specialized nuclear medicine nurse administering the dose worn a portable RD detector (SG-16A) throughout the procedure to measure the cumulative RD received during radioactive operations. The cumulative environmental RD was measured using a portable RD detector (SG-16A) which was placed on a shelf approximately 2 m away from the patient in the ward. Statistical analysis Other collected data were analyzed using SPSS v22.0 statistical software (IBM, USA) with a two-way repeated measures analysis of variance (Two-way ANOVA) to assess the impact of different [177Lu]Lu-DOTA-TATE treatment frequencies on the temporal changes in patients’ EDR. The Shapiro–Wilk test was used for normality testing, where p > 0.05 indicated data followed a normal distribution. For sphericity testing, if p > 0.05, the assumption of sphericity was met, otherwise, the results were corrected using the Greenhouse–Geisser method. Data were presented as mean ± standard deviation, and differences with p < 0.05 were considered statistically significant. Results Patients Basic information of the patients was presented in Table 1. Among the patients, there were 16 males and 14 females, with an average age of 53.3 ± 11.5 years (range 25–70 years). 18 patients have primary lesions located in the pancreas, while the other 12 patients have primary lesions in the rectum. Among the 30 patients, due to adverse reactions (thrombocytopenia), except for one patient who received only 2 cycles of [177Lu]Lu-DOTA-TATE treatment and two patients who received only 3 cycles, the remaining 27 patients completed 4 full cycles. Additionally, among the 27 patients, except for two patients whose last dose was reduced from 7.40 GBq to 3.70 GBq due to neutropenia, the rest patients received a dose of 7.40 GBq per treatment. And the actual average accumulated dose for patients treated with 2, 3 and 4 cycles were 15.44 GBq, 22.67 GBq and 29.89 GBq, respectively. The typical SPECT images of one patient were shown as follows. Figure 1 showed SPECT images of one patient at 4, 24, 96 and 144 h after the first [177Lu]Lu-DOTA-TATE treatment cycle. The patient was a 27-year-old young female diagnosed with pancreatic NEN with multiple liver and intra-abdominal lymph node metastases. Figure 2 displayed SPECT images at 4 h after four different cycles of the same patient. The SPECT images of the patient at A 4 h, B 24 h, C 96 h and D 144 h after the first treatment The SPECT images at 4 h after four treatment cycles of the patient. A First treatment cycle, B second treatment cycle, C third treatment cycle and D fourth treatment cycle EDR value decay curve fitting Figure 3 displayed the double exponential curve fitting results of EDR-1 m for the patient after receiving [177Lu]Lu-DOTA-TATE. The double exponential curve fitting results of EDR-1 m at various time points from the first to fourth treatment cycle were shown in Fig. 3A–D. Meanwhile, the Fig. 3E curve showed all the patients’ EDR values of four cycles. The mean EDR value of four cycles in different patients were calculated. And the double exponential curve was shown in Fig. 3F. The RMSE values could indicate the fitting degree, in our research all the fitting curve had a low RMSE value. In order to show the data distribution of EDR values, we added the EDR values decay line graph with error bars in Supplemental Fig. 1. The double exponential curve fitting results of EDR-1 m after [177Lu]Lu-DOTA-TATE treatments for the patients. A–D The double exponential curve fitting results of overall EDR-1 m at various time points from the first to fourth treatment cycle for patients. E The double exponential curve fitting results of overall EDR-1 m values of four cycles. F The double exponential curve fitting results of the mean EDR-1 m value at the same time points for each patient In addition, we conducted a Two-way ANOVA analysis of EDR-1 m values at different time points among different treatment cycles for the patients (Fig. 4). The Shapiro–Wilk analysis indicated that the data in each group followed a normal distribution (p > 0.05). The Two-way ANOVA analysis of EDR-1 m at different time points among patients receiving different cycles of treatments The Mauchly’s test of sphericity results showed that the Machly W = 0.005, p < 0.001. So, the sphericity assumption was not valid, the Greenhouse–Geisser correction was adopted (F = 1.610, p = 0.109), which indicated that there was no significant interaction between the factors of treatment cycles and post-treatment time points on the measured values of external RD rates. Further analysis focused on the main effects of the two factors on the measured values of external RD rates. For patients undergoing different numbers of treatments with [177Lu]Lu-DOTA-TATE, there were statistically significant differences in the post-treatment EDR-1 m among the groups (F = 5.614, p = 0.002). Pairwise comparisons revealed a statistical difference between the second and the fourth treatment groups (p = 0.004), while no statistical differences were found among the other pairwise comparisons (p > 0.05). Following each treatment administration, the EDR-1 m values gradually decreased over time. Within the 0–6 h timeframe, there were statistically significant differences in EDR-1 m at each time point (F = 33.08, p < 0.001). Figure 5 presented the double exponential curve fitting results for EDR during drug administration (0–40 min). Figure 5A–D displayed the double exponential curve fitting results for each time point from the first to fourth treatment cycle. The Fig. 5E double exponential fitting curve showed four cycles’ EDR values of all the patients. We collected the mean EDR value of four cycles, and the double exponential fitting curve was shown in Fig. 5F. The EDR values decay line graph with error bars during the drug administration was showed in Supplemental Fig. 2. The double exponential curve fitting results for EDR during drug administration for patients. A–D The overall EDR double exponential curve fitting results at various time points from the first to fourth treatment cycle for patients. E The overall EDR double exponential curve fitting results at various time points of four cycles. F The double exponential curve fitting results for the mean EDR value at the same time points during drug administration for each patient Radiation dose of direct family members The analysis of the double exponential fitting curve of the external RD equivalent rate showed two excretion phases: a fast initial clearance rate with a half-life of 1.10 ± 0.72 h, and a slow later clearance rate with a half-life of 158.11 ± 14.14 h. Table 2 indicated the total accumulated RD values estimated at different discharge times after treatment. The results showed that for direct adult family members of patients, immediate daily activity contact after injection resulted in a total accumulated RD exceeding 5 mSv (5.55 mSv) after four treatments. If the patient is discharged 24 h after the injection, the RD from daily contact activities with direct adult family members can be controlled to ≤ 5 mSv. For direct family members with children over 10 years old in the patient’s family, starting daily activities with the patient 48 h after injection ensured that the total accumulated RD does not exceed 3 mSv after four treatments. For direct family members with children aged 3–10 in the patient’s family and co-workers, starting daily contact at 144 and 192 h after the injection can keep the total accumulated RD under 1 mSv after four treatments. Table 2The cumulative RD to the public from a single [177Lu]Lu-DOTA-TATE treatment with different contact start times under different social activity patternsRD (μSv)Social activity patterns (contact distance 1.0 m)Day contact family (contact time 6 h/24 h)Colleagues at work (contact time 8 h/24 h)Immediately post-injection1388.12 ± 311.252288.68 ± 506.4824 h post-injection548.06 ± 85.71961.60 ± 150.2048 h post-injection443.48 ± 48.39778.36 ± 84.79144 h post-injection234.78 ± 7.45412.64 ± 13.05192 h post-injection124.03 ± 1.51218.57 ± 2.64 The cumulative RD to the public from a single [177Lu]Lu-DOTA-TATE treatment with different contact start times under different social activity patterns Radiation dose to staff Based on measurements taken by the portable RD detector worn by nuclear medicine specialized nurses during each administration, the cumulative RD received per administration by the nurses was calculated to be 1.40 ± 1.32 μSv (median 1.02, range 0.13–6.89). According to the occupational RD limit for radiation workers of 20 mSv, if calculated based on the mean value, a single nurse could administer treatments to over 14,000 patients per year. If calculated based on the highest RD received by a nurse in this study (6.89 μSv), a single nurse could administer treatments to over 2,900 patients per year, far exceeding the current workload of nuclear medicine nurses. Therefore, radiation exposure for injection nurses during [177Lu]Lu-DOTA-TATE therapy is deemed safe. Additionally, during each patient’s hospitalization, we measured the cumulative RD in the surrounding environment. For patients with measurement times of < 12 h, the average cumulative dose was 21.33 ± 17.40 μSv (median 17.40, range 3.69–101.40); for patients with measurement times of 24 h, the average cumulative dose was 23.41 ± 19.02 μSv (median 24.00, range 3.20–118.80), with no statistically significant difference between the two groups (p > 0.05). Discussion Previous studies have shown that [177Lu]Lu-DOTA-TATE can significantly benefit patients with SSTR-positive NENs in terms of PFS, objective response rate (ORR) and quality of life [24, 25]. The main adverse reaction of [177Lu]Lu-DOTA-TATE is gastrointestinal reactions (such as nausea, vomiting), but this is mainly related to the infusion of the amino acid solution, and the adverse reaction will alleviate as the amino acid infusion ends. A few adverse reactions are related to the experimental drug [177Lu]Lu-DOTA-TATE, including ≥ grade 3 platelet reduction, neutrophil reduction, and lymphocyte reduction [9, 26]. In our study, during the medication process in all patients, only 3 patients discontinued the medication midway due to platelet reduction adverse reactions, 2 patients had dose reduction, and 3 patients experienced temporary nausea and/or vomiting gastrointestinal reactions. It appeared that the use of [177Lu]Lu-DOTA-TATE for treating GEP-NENs patients was relatively safe. During the administration of [177Lu]Lu-DOTA-TATE, medical nurses and accompanying family members might be exposed to radiation risks. In this study, during the hospitalization of GEP-NENs patients, as shown in Fig. 3, we fitted the decay curves of each patient in the early stage and found significant differences between the two measurement points in different patients, with a large separation from the curve and significant heterogeneity, which could not well represent the overall radiation decay pattern of patients during treatment. Therefore, we selected data from 1 to 5 h after drug injection for decay curve fitting. To demonstrate the radiation decay pattern of the patients after [177Lu]Lu-DOTA-TATE treatment, we presented the fitting curve results for up to 8 d. We fitted the decay patterns of EDR-1 m for patients with different treatment frequencies separately and fitted the double exponential curves of the overall EDR-1 m for all patients at different treatment cycles and the mean EDR-1 m at the same time points for each patient. The results showed that R2 were relatively high and RMSE were relatively low, indicating a good fit of the curves, which could well reflect the population’s EDR decay pattern during [177Lu]Lu-DOTA-TATE treatment. However, the analysis of EDR-1 m for patient time and treatment frequency factors indicated that there were still differences in the EDR values among the population after receiving different treatment frequencies of [177Lu]Lu-DOTA-TATE (Fig. 4), which may be due to the small sample size in this study and individual differences among patients. Additionally, we also fitted the decay patterns of EDR at close distances to patients during the administration of [177Lu]Lu-DOTA-TATE, and the results showed very high R2 and low RMSE values, indicating that the EDR at close distances for different individuals during [177Lu]Lu-DOTA-TATE drug injection was similar, and the decay patterns were also similar (Fig. 5). This result indirectly suggests the RD that the treatment drug may generate for nurses working in close proximity to patients during [177Lu]Lu-DOTA-TATE administration. According to Fig. 5E, within 40 min of administration, patients undergoing [177Lu]Lu-DOTA-TATE treatment generated a RD of 133.10 μSv for nurses (199.65 μSv/h). Calculating based on the RD limit of 20 mSv for occupational radiation workers, nurses were allowed a time limit of approximately 100 h per year for close-range [177Lu]Lu-DOTA-TATE operations. Therefore, for nurses who need to perform close-range operations, it is necessary to master the operation process proficiently to reduce the time of each close-range operation. Furthermore, during the administration process, nurses implemented lead shielding measures to further reduce radiation damage. Additionally, personal dose measurements for the administering nurses during [177Lu]Lu-DOTA-TATE administration showed a mean single dose accumulation of only 1.40 μSv, indicating that the cumulative RD they received was low and safe. The regulations regarding the dose limits for radioactive isotopes vary from country to country. For example, the European Council Directive 2013/59/Euratom states that the dose limit for patients’ family members is consistent with that of the general public which is 1 mSv/year [27]. On the other hand, the International Commission on Radiological Protection (ICRP) recommends a dose limit of 1 mSv/year for the general public and 5 mSv/year for patients’ family members. While in China, specific dose limits are set at 1 mSv/year for direct family members with children aged 3–10 and 3 mSv/year for children above 10 years old. This study found that for GEP-NENs patients receiving four treatments of 7.40 GBq [177Lu]Lu-DOTA-TATE, failure to restrict their daily activities post-injection would result in the public exceeding national dose limits. Based on China’s relevant dose limit standards, we provided guidelines on the appropriate restriction times for personnel involved. The results showed that for hospitals offering [177Lu]Lu-DOTA-TATE therapy, with standardized post-discharge behavioral restrictions, whether outpatient or inpatient, the treatments would be safe and feasible. While tailored radiation protection guidance post-treatment based on individual circumstances was necessary. This study provided the first analysis of RD received by the public at various time points under different social activity models following [177Lu]Lu-DOTA-TATE treatment for GEP-NENs patients in China, serving as a reference for establishing relevant radiation protection standards. However, this study still has some limitations. Firstly, since [177Lu]Lu-DOTA-TATE is not yet commercially available in China and is still in the clinical trial phase, and the incidence of neuroendocrine tumors is relatively low, our sample size is not very large. Secondly, this study did not collect patients’ urine samples after the administration of [177Lu]Lu-DOTA-TATE, and did not estimate the residual radioactive activity in the patients’ bodies. Thirdly, when conducting EDR measurements in this study, we considered the measured values at a specific distance from the patient as the EDR results, however, [177Lu]Lu-DOTA-TATE is not distributed concentratedly in the patient’s body, so the measured EDR results may have some errors compared to the actual results. Additionally, we did not take into account the variability between different patients when conducting EDR measurements. In future studies with a larger sample size, we will incorporate these limiting factors into our research. Conclusions Clinical studies using [177Lu]Lu-DOTA-TATE for patients with neuroendocrine tumors are widely conducted in China, and radiation protection is crucial. By fitting and analyzing the overall decay pattern of EDR values measured during and after patient administration, we explored the decay pattern to assist in establishing post-administration patient hospitalization duration and post-discharge radiation protection standards for the public. In the end, we found that for GEP-NENs patients undergoing [177Lu]Lu-DOTA-TATE treatment, it was necessary to restrict their daily activities for at least 24 h to ensure that the RD for family members remains below 5 mSv. Supplementary Information Additional file1. Acknowledgements Not applicable. Abbreviations Gastroenteropancreatic neuroendocrine neoplasms External dose rate Radiation dose Somatostatin receptors Peptide receptor radionuclide therapy Progression-free survival Overall survival European medicines agency Food and drug administration National comprehensive cancer network Chinese society of clinical oncology External dose rate Fudan University Shanghai Cancer Center Positron emission tomography/computed tomography Upper limit of normal Alanine aminotransferase Glutamic pyruvic transaminase International normalized ratio Single photon emission computed tomography Low energy high resolution Ordered subset expectation maximization Radiation dose Root mean square error National council on radiation protection and measurements Objective response rate International commission on radiological protection Author contributions FL, PL and SS designed the studies; FL wrote the manuscript; JX, JZ and XX helped gathered the data; FL and PL analyzed the data; ZC, YQ, YL and JC participated in revising the manuscript; All authors contributed to the article and approved the submitted version. Funding This study was supported in part by the National Natural Science Foundation of China (82102097, U23A20465) and Science and Technology Commission of Shanghai Municipality (23DZ2291400, 23TS1400800). Availability of data and materials The datasets generated during and analyzed during the current study are available from the corresponding author on reasonable request. Declarations Ethics approval and consent to participate The study was approved by the Ethics Committee of FUSCC (Approval No. 2210262-2). All patients provided written informed consent to participate in the study. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Consent for publication Written informed consent for publication was obtained from all study participant. Competing interests The authors declare that they have no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Fei Liu and Panli Li have contributed equally to this work. Contributor Information Jie Chen, Email: chen0jie@hotmail.com. Shaoli Song, Email: shaoli-song@163.com. References Associated Data Supplementary Materials Additional file1. Data Availability Statement The datasets generated during and analyzed during the current study are available from the corresponding author on reasonable request.